Market Overview

Glaucoma Therapeutics Market was valued at USD 6.88 billion in 2022 and expected to grow at a CAGR of 5.6% during the forecast period. Glaucoma is a group of eye conditions that damage the optic nerve, which is responsible for transmitting visual signals from the eye to the brain. Glaucoma can lead to vision loss or blindness if left untreated. Glaucoma therapeutics refer to medications and treatments used to manage or prevent the progression of glaucoma.

The main objective of glaucoma therapeutics is to lower the intraocular pressure (IOP) within the eye, as high IOP is a major risk factor for glaucoma. The treatment options for glaucoma include eye drops, oral medications, laser therapy, and surgery.

Eye drops are the most common form of glaucoma therapy, as they are easy to use and are effective in reducing IOP. Eye drops work by either decreasing the amount of fluid produced in the eye or by increasing the amount of fluid that drains from the eye. Prostaglandin analogs, beta blockers, alpha agonists, and carbonic anhydrase inhibitors are the most commonly used eye drops for glaucoma treatment.

Oral medications are less commonly used for glaucoma treatment and are typically reserved for patients who do not respond well to eye drops. Carbonic anhydrase inhibitors and beta blockers are the most commonly prescribed oral medications for glaucoma.

Laser therapy and surgery are reserved for cases of severe or advanced glaucoma that do not respond to medications. Laser therapy involves using a high-energy laser to increase fluid drainage from the eye, while surgery involves creating a new drainage channel to reduce IOP.

The global glaucoma therapeutics market is expected to grow in the coming years, driven by factors such as the increasing prevalence of glaucoma, rising geriatric population, and increasing adoption of combination therapies for glaucoma treatment.

Eye drops are the most commonly used form of glaucoma therapy and are expected to hold the largest share of the market, driven by their ease of use and effectiveness in reducing intraocular pressure (IOP). Prostaglandin analogs are the most commonly prescribed eye drops for glaucoma treatment.

The carbonic anhydrase inhibitors segment is expected to grow at the highest rate due to the increasing use of combination therapies that include these medications, as well as the rising demand for oral medications in cases where eye drops are not effective.

North America is expected to hold the largest share of the glaucoma therapeutics market, driven by the high prevalence of glaucoma in the region and the availability of advanced healthcare infrastructure. However, the Asia-Pacific region is expected to grow at the highest rate due to the increasing geriatric population and rising healthcare expenditure in emerging economies such as India and China.

Overall, the glaucoma therapeutics market is expected to continue to grow globally, driven by factors such as the increasing prevalence of glaucoma, rising geriatric population, and increasing adoption of combination therapies for glaucoma treatment.

Report Scope

Impact of COVID

The COVID-19 pandemic has had a moderate impact on the glaucoma therapeutics market. While the demand for glaucoma treatments has remained stable, there have been disruptions in the supply chain and healthcare delivery systems, leading to delays in diagnosis and treatment of glaucoma patients.

The pandemic has also led to a shift towards telemedicine and remote healthcare services, which has had both positive and negative impacts on the glaucoma therapeutics market. On one hand, the use of telemedicine has made it easier for patients to access healthcare services from the safety of their homes, reducing the risk of virus transmission. On the other hand, remote consultations may not be as effective as in-person visits for the diagnosis and treatment of glaucoma, leading to delays in treatment and progression of the disease.

The pandemic has also led to a shortage of medical supplies and equipment, including glaucoma medications and diagnostic tools. This has led to an increase in the cost of these products, as well as delays in treatment and reduced access to healthcare for glaucoma patients.

Overall, the impact of COVID-19 on the glaucoma therapeutics market has been moderate, with disruptions in the supply chain and healthcare delivery systems leading to delays in diagnosis and treatment. However, the increasing adoption of telemedicine and remote healthcare services has provided some opportunities for the market, while the shortage of medical supplies and equipment has posed challenges.

Disease Type Insights

Open-angle glaucoma is the most common type of glaucoma, accounting for around 70-90% of all cases, while angle-closure glaucoma is less common, accounting for around 10-30% of cases.

Drug Class Insights

Prostaglandin analogs segment held the largest share of the global glaucoma therapeutics market in 2020, due to the high efficacy and relatively low side effects of these drugs. The beta blockers segment was the second largest, followed by adrenergic agonists and carbonic anhydrase inhibitors.

Distribution Channel Insights

Hospital pharmacy held the largest market share in 2022 due to the availability of a wider range of medications, higher purchasing power, and the ability to manage complex medical conditions. Retail pharmacy was the second-largest segment, followed by online pharmacy. However, the market share % by distribution channel may vary depending on the region and other factors.

Regional Insights

North America held the largest market share due to the high prevalence of glaucoma in the region, a large patient pool, and the presence of major market players. Europe was the second-largest segment, followed by Asia Pacific. The Asia Pacific market is expected to grow at a significant rate due to the increasing geriatric population, rising prevalence of glaucoma, and the growing demand for effective treatment options.

Competitive Analysis

Some of the major companies operating within the market are Bausch & Lomb Incorporated, Merck & Co., Inc., AERIE Pharmaceuticals, Inc., Akorn operating company LLC, Cipla Inc., AbbVie, Teva Pharmaceutical Industries Ltd., Inotek Pharmaceuticals, Pfizer Inc., Novartis AG, and Santen Pharmaceutical Co., Ltd. These players are focusing on product innovation, expansion, and partnerships to strengthen their market position and meet the growing demand for Cardiovascular Devices globally.

Why to buy this Report?

The report provides quantitative and qualitative aspect for the market in terms of value and volume, along with supporting market trends, challenges, restraints.

The report provides an in depth analysis from both production and consumption point of view at the regional and country level. Key Factors considered within the report scope are Production capacity by countries/regions, average price, consumption ratio, revenue earned and gross margin.

The report provides competitive analysis of around 30-50 companies operated in the market, these companies are bifurcated into niche players, the leaders and major contenders. The companies are analyzed in terms of following factors such as:

§  Business Model

§  Production Capacity, Revenue, Sales, Gross Margin

§  Key Business Strategy

§  SWOT Analysis

In terms of competitive landscape, the report provides distinctive factors that would help the end user in taking a key decision within the business:

§  Company Share Analysis from 2018-2022

§  Company Analysis by Revenue and Sales

§  Company Production Capacity, Gross Margin

§  Company Share Analysis by Application/End Use

§  Company Share Analysis by Product/Specification

Frequently Asked Questions

·         What is the market size and growth projections?

·         What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?

·         What are the top performing segments, and countries / regions of each of the markets?

·         What is the market size and growth rate across key countries / regions?

·         How big is the global & regional market in terms of revenue and volume?

·         How far market will grow in forecast period in terms of revenue and volume?

·         What factors will influence demand and supply trends across each markets during the forecast period?

·         What are the technology trends shaping various markets?

·         Which country / region has more opportunities?

·         What is the COVID-19 impact on the market and how long will it take to recover?

·         Who are the key competitors of market Players?

·         What are the market share (%) of Key Players?

·         What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?

·         What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?